Guardant Health (NASDAQ:GH) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Key Points

• Q1 beat and raised guidance — Guardant reported ($0.45) EPS, beating estimates by $0.02, with revenue of $302M (+48% YoY), surpassed $1B TTM revenue and raised 2026 revenue guidance to $1.30B–$1.32B.
• Shield screening gaining traction — Shield generated $42M from ~44k tests in Q1 with >90% adherence, expanded distribution (Quest, Asia rollout) and improved screening gross margin from 18% to 56%, with 2026 Shield guidance of $186M–$198M.
• Heavy reinvestment and cash burn — Non‑GAAP operating expenses rose 34% to $268M, adjusted EBITDA loss was $59M, Q1 free cash flow burned $71M and full‑year FCF burn is guided to $185M–$195M, though the company holds about $1.2B in cash.

Guardant Health (NASDAQ:GH - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.02, FiscalAI reports. The firm had revenue of $301.67 million during the quarter, compared to analyst estimates of $279.15 million. The business's quarterly revenue was up 48.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.49) EPS.

Here are the key takeaways from Guardant Health's conference call:

• Q1 beat and higher full‑year guide — Guardant reported $302M in Q1 revenue (+48% YoY), surpassed $1B TTM revenue, and raised 2026 guidance to $1.30B–$1.32B, signaling sustained top‑line momentum.
• Shield screening momentum and margin expansion — Shield generated $42M on ~44k tests in Q1, with >90% adherence, nationwide Quest distribution, a new 2‑tube FDA kit approval, Asia rollout with Manulife, and screening gross margin improvement from 18% to 56%; 2026 Shield guidance is $186M–$198M (~230k–245k tests).
• Oncology product and AI platform traction — Oncology revenue was $205M (+36%); Guardant360 Liquid volumes +30%, Guardant360 Tissue accelerating after whole‑transcriptome upgrade, and Reveal volumes >100% as InfinityAI/SmartApps drive deeper adoption; Guardant360 Liquid remains in FDA review.
• Biopharma/data partnerships and CDx momentum — Biopharma & data revenue was $53M (+17%), Guardant now supports 26 CDx approvals across regions, and strategic deals (e.g., Merck, Nuvalent) plus InfinityAI real‑world evidence are strengthening long‑term commercial pipelines.
• Higher operating spend and ongoing cash burn — Non‑GAAP operating expenses rose 34% to $268M (S&M growth), adjusted EBITDA loss remained $59M, Q1 free cash flow burn was $71M and full‑year FCF burn is guided to $185M–$195M; the company has ~$1.2B cash but continues to reinvest heavily, which may pressure near‑term profitability.

Guardant Health Stock Up 0.0%

NASDAQ:GH traded up $0.01 during trading hours on Thursday, reaching $92.26. 2,389,102 shares of the stock were exchanged, compared to its average volume of 2,172,853. The stock has a market capitalization of $12.23 billion, a P/E ratio of -27.87 and a beta of 1.48. The firm has a 50 day simple moving average of $88.93 and a 200-day simple moving average of $96.92. Guardant Health has a 52 week low of $36.36 and a 52 week high of $120.74.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 348 shares of the business's stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $88.09, for a total transaction of $30,655.32. Following the completion of the sale, the director owned 8,394 shares in the company, valued at $739,427.46. The trade was a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Terilyn J. Monroe sold 3,832 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $92.68, for a total transaction of $355,149.76. Following the sale, the insider directly owned 20,990 shares in the company, valued at $1,945,353.20. This trade represents a 15.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,596 shares of company stock valued at $775,767 over the last 90 days. Insiders own 6.10% of the company's stock.

Institutional Investors Weigh In On Guardant Health

Institutional investors have recently modified their holdings of the business. Parallel Advisors LLC boosted its stake in Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company's stock valued at $36,000 after acquiring an additional 219 shares during the period. EFG International AG acquired a new stake in shares of Guardant Health during the 4th quarter worth approximately $41,000. Kestra Advisory Services LLC acquired a new stake in shares of Guardant Health during the 4th quarter worth approximately $56,000. Itau Unibanco Holding S.A. bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $60,000. Finally, Danske Bank A S acquired a new position in Guardant Health during the 3rd quarter valued at approximately $62,000. Institutional investors own 92.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their target price on Guardant Health from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Friday, February 20th. Stifel Nicolaus raised their price objective on Guardant Health from $120.00 to $130.00 and gave the company a "buy" rating in a research note on Friday, February 20th. Citigroup lifted their price objective on Guardant Health from $135.00 to $150.00 and gave the stock a "buy" rating in a report on Friday, February 20th. Raymond James Financial reaffirmed an "outperform" rating and issued a $129.00 target price on shares of Guardant Health in a research report on Monday, February 23rd. Finally, TD Cowen raised their price target on shares of Guardant Health from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. Nineteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $128.63.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.